keyword
https://read.qxmd.com/read/38476783/exploring-esketamine-s-therapeutic-outcomes-as-an-fda-designated-breakthrough-for-treatment-resistant-depression-and-major-depressive-disorder-with-suicidal-intent-a-narrative-review
#1
REVIEW
Suneeta Kumari, Hassan A Chaudhry, Adam Sagot, Stacy Doumas, Hussain Abdullah, Eric Alcera, Ramon Solhkhah, Saba Afzal
The expansive spectrum of major depressive disorder (MDD) continues to pose challenges for psychiatrists to treat effectively. Oral antidepressant (OAD) medications that alter monoamine neurotransmitters, mainly selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), have been the mainstay of therapy for decades. Although these drugs have been largely beneficial, a considerable subset of patients do not respond adequately to multiple conventional therapies administered for an appropriate length of time, leading to a diagnosis of treatment-resistant depression (TRD)...
February 2024: Curēus
https://read.qxmd.com/read/38459368/analgesia-for-rib-fractures-a-narrative-review
#2
REVIEW
Theunis van Zyl, Anthony M-H Ho, Gregory Klar, Christopher Haley, Adrienne K Ho, Susan Vasily, Glenio B Mizubuti
PURPOSE: Rib fracture(s) is a common and painful injury often associated with significant morbidity (e.g., respiratory complications) and high mortality rates, especially in the elderly. Risk stratification and prompt implementation of analgesic pathways using a multimodal analgesia approach comprise a primary endpoint of care to reduce morbidity and mortality associated with rib fractures. This narrative review aims to describe the most recent evidence and care pathways currently available, including risk stratification tools and pharmacologic and regional analgesic blocks frequently used as part of the broadly recommended multimodal analgesic approach...
March 8, 2024: Canadian Journal of Anaesthesia
https://read.qxmd.com/read/38431685/features-of-biliary-tract-diseases-in-ketamine-abusers-a-systematic-review-of-case-reports
#3
JOURNAL ARTICLE
Alireza Teymouri, Hadis Nasoori, Maryamsadat Fakheri, Aref Nasiri
BACKGROUND AND AIMS: Anesthesiologists prefer ketamine for certain surgeries due to its effectiveness as a non-competitive inhibitor of the N-methyl-D-aspartate receptor in the brain. Recently, this agent has also shown promise as an antidepressant. However, ketamine can cause hallucinogenic effects and is sometimes abused as an illicit drug. Ketamine abuse has been associated with liver and bile duct complications. This systematic study aims to better understand cholangiopathy in ketamine abusers by reviewing case reports...
March 3, 2024: Journal of Medical Case Reports
https://read.qxmd.com/read/38386251/recent-advances-in-the-treatment-of-treatment-resistant-depression-a-narrative-review-of-literature-published-from-2018-to-2023
#4
REVIEW
John L Havlik, Syed Wahid, Kayla M Teopiz, Roger S McIntyre, John H Krystal, Taeho Greg Rhee
PURPOSE OF REVIEW: We review recent advances in the treatment of treatment-resistant depression (TRD), a disorder with very limited treatment options until recently. We examine advances in psychotherapeutic, psychopharmacologic, and interventional psychiatry approaches to treatment of TRD. We also highlight various definitions of TRD in recent scientific literature. RECENT FINDINGS: Recent evidence suggests some forms of psychotherapy can be effective as adjunctive treatments for TRD, but not as monotherapies alone...
February 22, 2024: Current Psychiatry Reports
https://read.qxmd.com/read/38309683/effectiveness-and-safety-of-intravenous-medications-for-the-management-of-acute-disturbance-agitation-and-other-escalating-behaviours-a-systematic-review-of-prospective-interventional-studies
#5
REVIEW
Megan Castro, Matt Butler, Alysha Naomi Thompson, Siobhan Gee, Sotiris Posporelis
Acute disturbance is a broad term referring to escalating behaviours secondary to a change in mental state, such as agitation, aggression, and violence. Available management options include de-escalation techniques and rapid tranquilisation, mostly via parenteral formulations of medication. Whilst the intramuscular route has been extensively studied in a range of clinical settings, the same cannot be said for intravenous (IV); this is despite potential benefits, including rapid absorption and complete bioavailability...
February 1, 2024: Journal of the Academy of Consultation—Liaison Psychiatry
https://read.qxmd.com/read/38268571/trauma-informed-care-in-psychedelic-therapy-research-a-qualitative-literature-review-of-evidence-based-psychotherapy-interventions-in-ptsd-and-psychedelic-therapy-across-conditions
#6
REVIEW
Nadav Liam Modlin, Michael Creed, Maria Sarang, Carolina Maggio, James J Rucker, Victoria Williamson
INTRODUCTION: Post-traumatic stress disorder (PTSD) is associated with significant patient burden. While pharmacotherapies and evidence-based psychotherapy interventions (EBPI) are effective, studies consistently highlight inadequate outcomes and high treatment dropout. Psychedelic therapy (PT) has shown preliminary promise across difficult-to-treat conditions, including MDMA-assisted therapy for PTSD, however trials of classical psychedelics in PTSD are lacking. Understanding patients' experiences of EBPI could help promote safety in PT...
2024: Neuropsychiatric Disease and Treatment
https://read.qxmd.com/read/38144471/short-term-ketamine-use-in-bipolar-depression-a-review-of-the-evidence-for-short-term-treatment-management
#7
REVIEW
Alina Wilkowska, Wiesław Jerzy Cubała
Bipolar depression constitutes a major problem in psychiatry. It correlates with high suicidality, treatment resistance, chronicity, and poor quality of life. Registered treatment for bipolar depression is limited and insufficient. There is an urgent need for implementing new therapeutic strategies. Intranasal ketamine's enantiomer-esketamine is a novel rapid-acting antidepressant with proven efficacy in treatment-resistant depression. Research on bipolar depression, although not as comprehensive, indicates that it may be a viable and safe substitute with minimal risk for mood polarity changes...
2023: Frontiers in Psychiatry
https://read.qxmd.com/read/38078017/perioperative-pain-management-and-cancer-outcomes-a-narrative-review
#8
REVIEW
Maria F Ramirez, Amanda Strang, Gavin Roland, Javier Lasala, Pascal Owusu-Agyemang
Cancer-related pain is one of the most common and incapacitating symptoms for cancer patients. Cancer pain can be caused by diagnostic or therapeutic procedures, side effects and toxicity from therapy, or the cancer itself. Uncontrolled cancer-related pain is associated with inadequate quality of life and reduced functional status. Optimal pain management during the perioperative period requires a tailored approach. Interventions that are recommended for the management of acute surgical pain include regional anesthesia, local anesthetic infusions, non-opioid analgesics (ketamine, dexmedetomidine, lidocaine, and non-steroidal anti-inflammatory drugs), and opioids...
2023: Journal of Pain Research
https://read.qxmd.com/read/37961848/what-clinicians-need-to-know-about-intranasal-esketamine-for-treatment-resistant-depression
#9
REVIEW
Judy Hope, David Copolov, John Tiller, Megan Galbally, Malcolm Hopwood, Richard Newton, Nicholas A Keks
OBJECTIVE: To review the usefulness of esketamine for treatment-resistant depression. METHOD: Pivotal trials of intranasal esketamine in treatment-resistant depression were synthesized as a narrative review. RESULTS: Esketamine is postulated to act through antagonism of N-methyl-D-aspartate (NMDA) glutamate receptors, but opioidergic effects may also be involved. Unlike intravenous ketamine, esketamine is given intranasally (under clinical observation), usually in addition to an oral antidepressant...
December 2023: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://read.qxmd.com/read/37893464/effectiveness-of-intranasal-analgesia-in-the-emergency-department
#10
REVIEW
Christian Zanza, Francesco Saglietti, Jacopo Davide Giamello, Gabriele Savioli, Davide Maria Biancone, Mario Giosuè Balzanelli, Benedetta Giordano, Anna Chiara Trompeo, Yaroslava Longhitano
In the Emergency Department (ED), pain is one of the symptoms that are most frequently reported, making it one of the most significant issues for the emergency physician, but it is frequently under-treated. Intravenous (IV), oral (PO), and intramuscular (IM) delivery are the standard methods for administering acute pain relief. Firstly, we compared the safety and efficacy of IN analgesia to other conventional routes of analgesia to assess if IN analgesia may be an alternative for the management of acute pain in ED...
September 29, 2023: Medicina
https://read.qxmd.com/read/37882811/oral-ketamine-may-offer-a-solution-to-the-ketamine-conundrum
#11
REVIEW
Megan Dutton, Adem T Can, Jim Lagopoulos, Daniel F Hermens
Ketamine has received considerable attention for its rapid and robust antidepressant response over the past decade. Current evidence, in clinical populations, predominantly relates to parenterally administered ketamine, which is reported to produce significant undesirable side effects, with additional concerns regarding long-term safety and abuse potential. Attempts to produce a similar drug to ketamine, without the psychotomimetic side effects, have proved elusive. Orally administered ketamine has a different pharmacological profile to parentally administered ketamine, suggesting it may be a viable alternative...
December 2023: Psychopharmacology
https://read.qxmd.com/read/37596559/intranasal-analgesia-for-acute-moderate-to-severe-pain-in-children-a-systematic-review-and-meta-analysis
#12
JOURNAL ARTICLE
Marcus Glenton Prescott, Ekaterina Iakovleva, Melanie Rae Simpson, Sindre Andre Pedersen, Daniel Munblit, Odd Martin Vallersnes, Bjarne Austad
BACKGROUND: Children in acute pain often receive inadequate pain relief, partly from difficulties administering injectable analgesics. A rapid-acting, intranasal (IN) analgesic may be an alternative to other parenteral routes of administration. Our review compares the efficacy, safety, and acceptability of intranasal analgesia to intravenous (IV) and intramuscular (IM) administration; and to compare different intranasal agents. METHODS: We searched Cochrane Library, MEDLINE/PubMed, Embase, Web of Knowledge, Clinicaltrials...
August 18, 2023: BMC Pediatrics
https://read.qxmd.com/read/37594256/rapid-sequence-intubation-is-it-time-to-find-an-alternative-induction-agent-a-narrative-review
#13
REVIEW
Brett A Faine, Elisabeth Carroll, Archit Sharma, Nicholas Mohr
OBJECTIVE: To review the efficacy, safety, and place in therapy of fentanyl as an induction agent for rapid sequence intubation (RSI) in critically ill patients. DATA SOURCES: A comprehensive search of PubMed, EMBASE, and clinical trial registries (1964-June 2021) was performed utilizing the keywords fentanyl, rapid sequence intubation, intubation, induction, anesthesia, hemodynamics, operating room (OR), and emergency. STUDY SELECTION AND DATA EXTRACTION: Only primary literature evaluating fentanyl in combination with a sedative or as the sole induction agent was included in the final analysis...
August 18, 2023: Journal of Pharmacy Practice
https://read.qxmd.com/read/37521706/the-cellular-mechanisms-associated-with-the-anesthetic-and-neuroprotective-properties-of-xenon-a-systematic-review-of-the-preclinical-literature
#14
Steven McGuigan, Daniel J Marie, Liam J O'Bryan, Francisco J Flores, Lisbeth Evered, Brendan Silbert, David A Scott
INTRODUCTION: Xenon exhibits significant neuroprotection against a wide range of neurological insults in animal models. However, clinical evidence that xenon improves outcomes in human studies of neurological injury remains elusive. Previous reviews of xenon's method of action have not been performed in a systematic manner. The aim of this review is to provide a comprehensive summary of the evidence underlying the cellular interactions responsible for two phenomena associated with xenon administration: anesthesia and neuroprotection...
2023: Frontiers in Neuroscience
https://read.qxmd.com/read/37334018/ketamine-induced-uropathy-a-narrative-systemic-review-of-surgical-outcomes-of-reconstructive-surgery
#15
REVIEW
Gabriel Vizgan, Michael Huamán, Kevin Rychik, Max Edeson, Jerry G Blaivas
AIMS: Refractory ketamine-induced uropathy (KU) (RKU) has devastating effects on the lower urinary tract leading to ureteral obstruction and even renal failure. The only effective treatment for RKU is major surgical reconstruction or urinary diversion. Nevertheless, there is a paucity of awareness about this destructive condition; the aim of this study is to conduct a narrative systemic review of all surgical outcomes of RKU. METHODS: This is an English language literature review of surgical outcomes in KU patients who underwent reconstructive lower urinary tract surgery or urinary diversion through 5 August 2022...
July 2023: BJUI compass
https://read.qxmd.com/read/37313271/ketamine-propofol-ketofol-in-procedural-sedation-a-narrative-review
#16
REVIEW
Eun-Ji Choi, Cheul-Hong Kim, Ji-Young Yoon, Eun-Jung Kim
Sedation methods for dental treatment are increasingly explored. Recently, ketofol, which is a combination of ketamine and propofol, has been increasingly used because the advantages and disadvantages of propofol and ketamine complement each other and increase their effectiveness. In this review, we discuss the pharmacology of ketamine and propofol, use of ketofol in various clinical situations, and differences in efficacy between ketofol and other sedatives.
June 2023: Journal of Dental Anesthesia and Pain Medicine
https://read.qxmd.com/read/37301324/ketamine-a-practical-review-for-the-consultation-liaison-psychiatrist
#17
REVIEW
Anastasia B Evanoff, Mirza Baig, John B Taylor, Scott R Beach
BACKGROUND: Ketamine is a noncompetitive N-methyl-D-aspartate-receptor antagonist often used for sedation and management of acute agitation in general hospital settings. Many hospitals now include ketamine as part of their standard agitation protocol, and consultation-liaison psychiatrists frequently find themselves treating patients who have received ketamine, despite lack of clear recommendations for management. OBJECTIVE: Conduct a nonsystematic narrative regarding the use of ketamine for agitation and continuous sedation, including benefits and adverse psychiatric effects...
June 8, 2023: Journal of the Academy of Consultation—Liaison Psychiatry
https://read.qxmd.com/read/37273364/ketamine-treatment-for-alcohol-use-disorder-a-systematic-review
#18
REVIEW
Michael Kelson, Justin M Burnett, Amy Matthews, Tony Juneja
Alcohol use disorder (AUD) is a chronic, recurrent condition that demonstrates significant heterogeneity in treatment response to first-line agents. Ketamine may have a therapeutic role in substance use disorders; however, research on this topic is limited. The objective of this systematic review is to qualitatively synthesize the current evidence of ketamine treatment for alcohol use disorder and evaluate its efficacy. A systematic review of Medline, PsycINFO, CINAHL, the Cochrane Library, and Google Scholar was performed to identify completed human studies in English or Spanish (from inception to July 2022) that assess the effectiveness of ketamine therapy for alcohol use disorder...
May 2023: Curēus
https://read.qxmd.com/read/37245947/ketamine-for-complex-regional-pain-syndrome-a-narrative-review-highlighting-dosing-practices-and-treatment-response
#19
REVIEW
Theresa R Lii, Vinita Singh
This is a narrative review of intravenous ketamine infusions for the treatment of complex regional pain syndrome (CRPS). It briefly covers the definition of CRPS, its epidemiology, and other treatments before introducing ketamine as the article's focus. A summary of ketamine's evidence base and its mechanisms of action is provided. The authors then review ketamine dosages reported in peer-reviewed literature for the treatment of CRPS, and their associated duration of pain relief. The observed response rates to ketamine and predictors of treatment response are also discussed...
June 2023: Anesthesiology Clinics
https://read.qxmd.com/read/37240943/recent-developments-in-pharmacotherapy-of-depression-bench-to-bedside
#20
REVIEW
Mujeeb U Shad
For the last 70 years, we did not move beyond the monoamine hypothesis of depression until the approval of the S-enantiomer of ketamine, an N-methyl-D-aspartate (NMDA) receptor blocker and the first non-monoaminergic antidepressant characterized by rapid antidepressant and antisuicidal effects. A similar profile has been reported with another NMDA receptor antagonist, dextromethorphan, which has also been approved to manage depression in combination with bupropion. More recently, the approval of a positive allosteric modulator of GABA-A receptors, brexanolone, has added to the list of recent breakthroughs with the relatively rapid onset of antidepressant efficacy...
April 29, 2023: Journal of Personalized Medicine
keyword
keyword
80944
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.